EPR earnings call for the period ending December 31, 2020.
The "Portugal Cards and Payments - Opportunities and Risks to 2024" report has been added to ResearchAndMarkets.com's offering.
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Disposable Surgical Devices Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2020-2027”LOS ANGELES, April 23, 2021 (GLOBE NEWSWIRE) -- The Global Disposable Surgical Devices Market is expected to grow at a CAGR of around 7.7% from 2020 to 2027 and reach the market value of over US$ 11.3 Bn by 2027. The North American disposable surgical device market is expected to dominate the global market. Government initiatives, a large patient pool, well-established healthcare infrastructure, increased adoption of advanced technology, and growing awareness about infection control and cross-contamination in the medical and healthcare fields are some of the major factors driving the growth of the global disposable surgical devices market. On the other hand, Asia Pacific is expected to have the fastest growing CAGR during the forecast period. The rising prevalence of chronic diseases as a result of sedentary lifestyles, as well as the presence of a large number of players involved in the development of medical disposable products, such as India and Japan, is expected to drive the growth of the global disposable surgical devices market. DOWNLOAD SAMPLE PAGES OF THIS REPORT@ https://www.acumenresearchandconsulting.com/request-sample/2586 Market Dynamics The rising incidence of hospital-acquired infections and diseases, as well as the increased emphasis on infection prevention, are driving the growth of the global disposable surgical devices market. According to World Health Organization (WHO) data, the prevalence of healthcare-associated infection ranged from 3.5% to 12% in developed countries, and it ranged from 5.7% to 19.1% in low and middle-income countries. Rising geriatric population, boost in incontinence problems, some mandatory guidelines that must be followed for patient safety, and increasing demand for sophisticated healthcare facilities are some of the key factors driving the global disposable surgical devices market. However, the mixed impact on the medical disposables market can be attributed to factors such as health insurance concerns, which have raised patient copayments and limited coverage for various medical services, as well as discouraging people from visiting hospitals for unnecessary reasons. Cost-cutting in healthcare One of the factors that may impede the growth of the global disposable surgical devices market is the presence of substitute products. VIEW TABLE OF CONTENT OF THIS REPORT@ https://www.acumenresearchandconsulting.com/disposable-surgical-devices-market COVID-19 impact act positively on the growth of the global disposable surgical devices market The emergence of a new corona virus pandemic has increased demand for disposable surgical devices. The COVID-19 strain is highly contagious and can spread quickly. To avoid this transmission, hospitals and clinics have switched from reusable to disposable instruments. As a result of all of these factors, the disposable surgical devices market is expected to grow rapidly during the pandemic. Segmental Outlook The global disposable surgical devices market is segmented based on product and application. Product is segmented as surgical sutures & staplers, handheld surgical devices, and electrosurgical devices. By application, the market is segmented as neurosurgery, plastic & reconstructive surgery, wound closure, obstetrics & gynecology, cardiovascular, orthopedic, general surgery, and others Competitive Landscape The major players involved in the disposable surgical devices market involve B. Braun, Smith & Nephew plc, Aspen Surgical, Alcon, Zimmer Biomet, Medtronic plc, Becton, Dickinson and Company, Ethicon, Inc., CooperSurgical, Inc., Surgical Innovations, and among others. Browse Upcoming Market Research Reports@ https://www.acumenresearchandconsulting.com/forthcoming-reports Some of the key observations regarding disposable surgical devices industry include: In December 2020, Zimmer Biomet announced an acquisition with A&E Medical Corporation. Zimmer Biomet has acquired A&E Medical and its complete portfolio of sternal closure devices – including sterna sutures, cable systems, and rigid fixation – along with a range of single-use complimentary temporary pacing wire and surgical punch products. In November 2020, Surgical Innovations announced a collaboration with the Centre for Sustainable Healthcare ("CSH"). This new collaboration with CSH will enable the validation of the Company's environmental messaging and demonstrate the quantifiable cost and environmental savings from a 'greener' operating room. This data will then help develop information and training for NHS hospitals and staff as they seek to fulfill obligations on sustainability in the NHS, and follow the publication in October 2020 of the NHS 'Net Zero' objective.In October 2016, Becton, Dickinson and Company announced joint venture with Apax Partners. The closing finalizes the sale of 50.1 percent interest in BD's Respiratory Solutions business to funds advised by Apax Partners, a leading global private equity firm. Vyaire Medical includes all business lines within BD's Respiratory Solutions business, including Ventilation, Respiratory Diagnostics, Vital Signs, and AirLife. INQUIRY BEFORE BUYING@ https://www.acumenresearchandconsulting.com/inquiry-before-buying/2586 BUY THIS PREMIUM RESEARCH REPORT - https://www.acumenresearchandconsulting.com/buy-now/0/2586 Would like to place an order or any question, please feel free to contact at sales@acumenresearchandconsulting.com | +1 407 915 4157 For Latest Update Follow Us: https://twitter.com/AcumenRC https://www.facebook.com/acumenresearchandconsulting https://www.linkedin.com/company/acumen-research-and-consulting
The "Consumer Appliances in Brazil" report has been added to ResearchAndMarkets.com's offering.
Global Tobacco Market 2021-2025 The analyst has been monitoring the tobacco market and it is poised to grow by $ 146. 50 bn during 2021-2025, progressing at a CAGR of almost 4% during the forecast period.New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Tobacco Market 2021-2025" - https://www.reportlinker.com/p03712204/?utm_source=GNW Our report on tobacco market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing new product launches and rising demand for cigars and smoking tobacco products. In addition, increasing new product launches is anticipated to boost the growth of the market as well.The tobacco market analysis includes end-user segment and geographic landscape.The tobacco market is segmented as below:By End-User• Combustible tobacco products• Smokeless tobacco productsBy Geography• APAC• Europe• North America• MEA• South AmericaThis study identifies the increasing organized retail outlets selling tobacco productsas one of the prime reasons driving the tobacco market growth during the next few years.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on tobacco market covers the following areas:• Tobacco market sizing• Tobacco market forecast• Tobacco market industry analysisThis robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading tobacco market vendors that include Altria Group Inc., British American Tobacco Plc, Djarum, Imperial Brands Plc, JT International SA, Philip Morris International Inc., Poschl Tabak GmbH and Co. KG, Pyxus International Inc., Scandinavian Tobacco Group AS, and Vector Group Ltd. Also, the tobacco market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.Read the full report: https://www.reportlinker.com/p03712204/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
Cindy A. Kitner, CPA, President and Chief Executive Officer of Jefferson Security Bank, was recently appointed to the FDIC’s Advisory Committee on Community Banking. The Advisory Committee, which meets several times per year, provides advice and recommendations to the FDIC on a broad range of community bank policy and regulatory matters. Kitner is one of 17 members on the Advisory Committee, which is represented by a cross-section of community bankers from around the country.
Europe's drug regulator reiterated on Friday that benefits of AstraZeneca's COVID-19 vaccine outweigh any risks, as part of a detailed guidance from ongoing reviews into rare blood clots to help individual nations determine the shot's use. The renewed backing comes after several countries in the European Union and worldwide have limited the use of the vaccine, known as Vaxzevria, while Denmark has stopped its use altogether, after possible links to clotting issues were confirmed. The interim analysis by a committee of the European Medicines Agency (EMA) determined that serious side effects of rare blood clots are likely to occur in 1 out of 100,000 vaccinated people, the regulator said in a statement.
EU financial services firms prioritise London with increased demand for UK authorisation
The "Freight Transport by Road in South Africa 2021" report has been added to ResearchAndMarkets.com's offering.
(Bloomberg) -- Stocks climbed after strong economic data added to evidence the recovery is gaining momentum, with traders also assessing a batch of corporate earnings. The dollar retreated.Most major groups in the S&P 500 advanced, led by financial, commodity and tech shares. The Russell 2000 of small caps outperformed major benchmarks. Tesla Inc. and Apple Inc. paced gains in megacap stocks. Snap Inc. rallied as the social-media giant’s user growth beat estimates, while footwear maker Skechers USA surged on an upbeat outlook. Blue chips Honeywell International Inc., American Express Co. and Intel Corp. weighed on the Dow Jones Industrial Average.Data Friday showed that U.S. new-home sales rebounded sharply in March to the highest since 2006, suggesting that the housing market is back on track. Meanwhile, a gauge of output at American manufacturers and service providers reached a record high in April, adding to evidence of stronger demand.Other corporate highlights:Kimberly-Clark Corp., the maker of Scott toilet paper, slid on steep sales declines that signaled the potential end of a boon triggered by the pandemic.Schlumberger, the world’s biggest crude contractor, said it expects a gradual recovery of oil demand to boost overseas work through the end of this year.Equities whipsawed this week amid a flare-up in global coronavirus cases and news that the White House plans to propose almost doubling the capital-gain tax rate for the wealthy. As stocks traded near all-time highs, traders also waded through corporate earnings and economic figures to get a sense on the pace of a rebound in activity.“A phrase I have heard a lot over the last couple of weeks is that the market is in a ‘wait and see’ mode,” wrote Chris Iggo, chief investment officer of core investments at AXA Investment Managers. “The consensus is clear, and we are waiting for the data to confirm that the global economy is at the beginning of a long expansion.”Comparing U.S. stocks to high-yield bonds makes equities “look less stretched,” according to Jeroen Blokland, a manager of multi-asset funds at Robeco. While the Cboe Volatility Index, or the VIX, set a 14-month low last week, the yield spread for the Bloomberg Barclays U.S. Corporate High-Yield Index reached its narrowest since July 2007 in the previous week. “Equities are relatively attractive versus high yield” on this basis, he wrote in a blog post.These are some of the main moves in markets:StocksThe S&P 500 climbed 0.5% at 10:32 a.m. New York time.The Stoxx Europe 600 Index declined 0.4%.The MSCI All-Country World Index rose 0.4%.CurrenciesThe Bloomberg Dollar Spot Index fell 0.3%.The euro climbed 0.4% to $1.2062.The Japanese yen was little changed at 107.95 per dollar.BondsThe yield on 10-year Treasuries climbed four basis points to 1.58%.Germany’s 10-year yield was unchanged at -0.25%.Britain’s 10-year yield rose one basis point to 0.754%.CommoditiesWest Texas Intermediate crude climbed 1.4% to $62.31 a barrel.Gold declined 0.5% to $1,773.10 an ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Gymnast Simone Biles captured the attention of sports fans for her talent both on the mat and off, such as the backflip she performed on the pitcher's mound in Houston before throwing out the first pitch during the 2019 World Series. Now she's attracted the attention of Gap's (NYSE: GPS) Athleta brand, which announced today that it has signed the sports star to represent the athleisure apparel company under a long-term contract. It's a major blow to Nike (NYSE: NKE), as Biles was a brand ambassador for the sporting goods company, though she never figured prominently in any of its ads.
For well over a month now, the IRS has been busy issuing stimulus checks to eligible Americans. Since the $1.9 trillion American Rescue Plan was signed into law, the IRS has been furiously blasting out stimulus payments in batches. This week, the IRS issued a sixth batch of $1,400 checks to reach more recipients.
U.S. investment fund Davidson Kempner and British investment firm Pioneer Point Partners will jointly invest up to 3.5 billion euros ($4.2 billion) by 2025 in a large-scale data centre in Portugal to tap demand from global tech firms. The two companies said in a joint statement on Friday the campus in the city of Sines, 150 km (93 miles) south of the capital Lisbon, will include five buildings with a useful capacity to supply up to 450 megawatts of cheap energy from renewable sources to the servers. Prime Minister Antonio Costa later hailed the project as "the largest foreign direct investment in Portugal in recent decades", expecting Sines to attract further foreign investment with a government plan to install a green hydrogen production hub there.
PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GlaxoSmithKline (GSK)First AnaptysBio-Generated Antibody, of 8 Currently Under Clinical Development, to Obtain Regulatory Approval in Europe$10MM Milestone Payment Earned by AnaptysBio Upon EC Approval; Additional $35MM and $165MM Milestones Due Upon Dostarlimab Regulatory and Commercial Milestones, RespectivelyAnaptysBio Due to Receive 8% to 25% Royalty on Global Net Sales of Dostarlimab SAN DIEGO, April 23, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the European Commission has granted conditional marketing authorization for JEMPERLI (dostarlimab) for use in women with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer who have progressed on or following prior treatment with a platinum containing regimen. The approval makes dostarlimab the first anti-PD-1 therapy available for endometrial cancer in Europe. JEMPERLI was generated by AnaptysBio using its proprietary somatic hypermutation (SHM) antibody platform and subsequently developed by TESARO, Inc., now a part of GSK, under a collaboration agreement. Eight AnaptysBio-generated therapeutic antibodies have advanced into clinical development to date, and JEMPERLI is the first AnaptysBio-generated antibody to obtain regulatory approval. “We are delighted that JEMPERLI is the first AnaptysBio-generated antibody to be approved in Europe and look forward to meaningful potential future milestone and royalty revenue from our collaboration with GSK,” said Hamza Suria, president and chief executive officer of AnaptysBio. “These revenues will continue to support AnaptysBio’s primary value-creation strategy, which is focused on advancing wholly-owned first-in-class therapeutic antibodies through multiple upcoming clinical catalysts in 2021 and 2022.” JEMPERLI is indicated as a monotherapy for treatment of adult patients with recurrent or advanced dMMR/MSI-H endometrial cancer, who have progressed on, or are being dosed following, prior treatment with a platinum-containing regimen, and is the first indication approved by the European Commission for JEMPERLI. AnaptysBio has earned a $10.0 million milestone payment as a result of this approval. Earlier this month, AnaptysBio earned a $20.0 million milestone payment as a result of approval by the U.S. Food and Drug Administration for JEMPERLI in endometrial cancer. In 2020, AnaptysBio received milestone payments of $10.0 million and $5.0 million for the FDA’s and EMA’s acceptances of the BLA and Marketing Authorisation Application (MAA) filings for JEMPERLI, respectively. Earlier this year, FDA accepted a subsequent BLA filing for JEMPERLI for the treatment of adult patients with dMMR recurrent or advanced solid tumors who have progressed on or following prior treatment. AnaptysBio recently received a $10.0 million payment from GSK as a result of this milestone. Payments totaling an additional $35 million will be due to AnaptysBio upon the achievement of future regulatory milestones for JEMPERLI in the United States and Europe. Furthermore, $165 million in sales milestones are due to AnaptysBio upon achievement of certain annual JEMPERLI net sales revenues. Royalties due to AnaptysBio for dostarlimab range from 8% to 25% of global net sales, where AnaptysBio will receive 8% of annual global net sales below $1 billion, and 12-25% of net sales above $1 billion. JEMPERLI is also being developed by GSK for the treatment of other tumor types and treatment settings, including currently ongoing phase III trials in recurrent or primary advanced endometrial cancer in combination with chemotherapy standard of care (RUBY) and the phase III FIRST study of platinum-based therapy with dostarlimab and niraparib versus standard of care platinum-based therapy as first-line treatment of stage III or IV non-mucinous epithelial ovarian cancer. In addition, JEMPERLI is being evaluated as monotherapy and in combination therapy across multiple tumor types and other cancers, including platinum-resistant ovarian cancer, non-small cell lung cancer, multiple myeloma and melanoma. GSK continues to develop additional antibodies partnered with AnaptysBio, including cobolimab, an AnaptysBio-generated anti-TIM-3 antagonist antibody, and GSK4074386, an anti-LAG-3 antagonist antibody. Under the terms of the collaboration, AnaptysBio is due to receive development and regulatory milestone payments for each of the first two indications for each of these antibodies. AnaptysBio can potentially receive a total of $1.1 billion in aggregate milestone payments under this collaboration. In addition, AnaptysBio will receive royalties ranging from 4% to 8% on global net sales of cobolimab and GSK4074386 and 1% of GSK’s global net sales of ZEJULATM. Important Information for JEMPERLI in the EU IndicationJEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen. Immune-Mediated Adverse Reactions Immune-related adverse reactions, which may be severe or fatal, can occur in patients treated with antibodies blocking the programmed cell death protein-1 / programmed death-ligand 1 (PD-1/PD-L1) pathway, including JEMPERLI. While immune-related adverse reactions usually occur during treatment with PD-1/PD-L1 blocking antibodies, symptoms can also manifest after discontinuation of treatment. Immune-related adverse reactions may occur in any organ or tissue and may affect more than one body system simultaneously. Important immune-related adverse reactions listed in this section are not inclusive of all possible severe and fatal immune-related reactions. Early identification and management of immune-related adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Patients should be monitored for symptoms and signs of immune-related adverse reactions. Clinical chemistries, including liver tests and thyroid function tests, should be evaluated at baseline and periodically during treatment. For suspected immune-related adverse reactions, adequate evaluation including specialty consultation should be ensured. Based on the severity of the adverse reaction, treatment with JEMPERLI should be withheld or permanently discontinued and corticosteroids (1 to 2 mg/kg/day prednisone or equivalent) or other appropriate therapy administered. Upon improvement to Grade ≤1, corticosteroid taper should be initiated and continued for 1 month or longer. Based on limited data from clinical studies in patients whose immune-related adverse reactions could not be controlled with corticosteroid use, administration of other systemic immunosuppressants can be considered. Hormone replacement therapy for endocrinopathies should be instituted as warranted. Treatment with JEMPERLI should be permanently discontinued for any Grade 3 immune-related adverse reaction that recurs and for any Grade 4 immune-related adverse reaction toxicity, except for endocrinopathies that are controlled with replacement hormones and unless otherwise specified in the Summary of Product Characteristics (SmPC). Immune-Related Pneumonitis Pneumonitis has been reported in patients receiving JEMPERLI. Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other causes excluded. Patients should be managed with JEMPERLI treatment modifications and corticosteroids. Immune-related pneumonitis occurred in 7 (1.4%) of 515 patients, including Grade 2 (1.2%) and Grade 3 (0.2%) pneumonitis. Pneumonitis led to discontinuation of JEMPERLI in 3 (0.6%) patients. Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in all 7 patients experiencing pneumonitis. Pneumonitis resolved in 6 (85.7%) patients. Immune-Related ColitisJEMPERLI can cause immune-related colitis. Patients should be monitored for signs and symptoms of colitis and managed with treatment modifications, anti-diarrhoeal agents and corticosteroids. Colitis occurred in 8 (1.6%) patients, including Grade 2 (1.0%) and Grade 3 (0.6%) colitis. Colitis did not lead to discontinuation of JEMPERLI in any patients. Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in 2 (28.6%) patients. Colitis resolved in 6 (75.0%) patients experiencing colitis. Immune-Related HepatitisJEMPERLI can cause immune-related hepatitis. Patients should be monitored for changes in liver function periodically as indicated, based on clinical evaluation and managed with JEMPERLI treatment modifications and corticosteroids. Hepatitis occurred in 1 (0.2%) patient, which was Grade 3. Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required. Hepatitis did not lead to discontinuation of JEMPERLI and resolved. Immune-Mediated Endocrinopathies Hypothyroidism occurred in 37 (7.2%) patients, all of which were Grade 2. Hypothyroidism did not lead to discontinuation of JEMPERLI and resolved in 13 (35.1%) patients. Hyperthyroidism occurred in 10 (1.9%) patients, including Grade 2 (1.7%) and Grade 3 (0.2%). Hyperthyroidism did not lead to discontinuation of JEMPERLI and resolved in 8 (80%) patients. Thyroiditis occurred in 2 (0.4%) patients; both were Grade 2. Neither event of thyroiditis resolved; there were no discontinuations of JEMPERLI due to thyroiditis. Adrenal insufficiency occurred in 7 (1.4%) patients, including Grade 2 (0.8%), and Grade 3 (0.6%). Adrenal insufficiency resulted in discontinuation of JEMPERLI in 1 (0.2%) patient and resolved in 2 (28.6%) patients. Immune-Mediated Nephritis Nephritis, including tubulointerstitial nephritis, occurred in 3 (0.6%) patients; all were Grade 2. Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in 2 (66.7%) patients experiencing nephritis. Nephritis led to discontinuation of JEMPERLI in 1 (0.2%) patient and resolved in 2 of 3 (66.7%) patients. Immune-Related RashImmune-related rash occurred in 17 (3.3%) patients, including Grade 3 in 6 (1.2%) patients receiving JEMPERLI. The median time to onset of rash was 41 days (range 2 days to 407 days). Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in 5 (29%) patients experiencing rash. Rash did not lead to discontinuation of JEMPERLI and resolved in 13 (76.5%) patients. Immune-Related ArthralgiaImmune-related arthralgia occurred in 21 (4.1%) patients. Grade 3 immune-related arthralgia was reported in 3 (0.6%) patients receiving JEMPERLI. The median time to onset of arthralgia was 87 days (range 1 day to 783 days). Systemic corticosteroids (prednisone ≥ 40 mg per day or equivalent) were required in 2 (9.5%) patients experiencing arthralgia. Arthralgia did not lead to discontinuation of JEMPERLI and resolved in 8 (38%) patients experiencing arthralgia. Other Immune-Related Adverse ReactionsGiven the mechanism of action of JEMPERLI other potential immune-related adverse reactions may occur, including potentially serious events [e.g. myositis, myocarditis, encephalitis, demyelinating neuropathy (including Guillain Barré syndrome), sarcoidosis]. Clinically significant immune-related adverse reactions reported in less than 1% of patients treated with JEMPERLI as monotherapy in clinical studies include autoimmune haemolytic anaemia, pancreatitis, iridocyclitis, uveitis and diabetic ketoacidosis. Patients should be monitored for signs and symptoms of immune-related adverse reactions and managed as described in the SmPC. Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors. Treatment with JEMPERLI may increase the risk of rejection in solid organ transplant recipients. The benefit of treatment with JEMPERLI versus the risk of possible organ rejection should be considered in these patients. Fatal and other serious complications can occur in patients who receive allogeneic haematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1–blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GvHD), acute GvHD, chronic GvHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1–blocking antibody prior to or after an allogeneic HSCT. Infusion-Related Reactions Infusion-related reactions including hypersensitivity occurred in 7 (1.4%) patients, including Grade 2 (1.2%) and Grade 3 (0.2%) infusion-related reactions. All patients recovered from the infusion-related reaction. ImmunogenicityAnti-drug antibodies (ADA) were tested in 315 patients who received JEMPERLI and the incidence of JEMPERLI treatment-emergent ADAs was 2.5%. Neutralising antibodies were detected in 1.3% of patients. In the patients who developed anti-JEMPERLI antibodies, there was no evidence of altered efficacy or safety of JEMPERLI. Elderly populationOf the 515 patients treated with JEMPERLI monotherapy, 50.7% were under 65 years, 37.9% were 65-75 years, and 11.5% were 75 years or older. No overall differences in safety were reported between elderly (≥ 65 years) and younger patients (< 65 years). Pregnancy, Lactation and FertilityJEMPERLI is not recommended during pregnancy and in women of childbearing potential not using contraception. JEMPERLI should not be used during breast-feeding and breast-feeding should be avoided for at least 4 months after the last dose of JEMPERLI. Fertility studies have not been conducted with JEMPERLI. COMMON ADVERSE REACTIONSJEMPERLI is most commonly associated with immune-related adverse reactions. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of JEMPERLI. In patients with advanced or recurrent solid tumours (N = 515), the most common adverse reactions (> 10%) were anaemia (25.6%), nausea (25.0%), diarrhoea (22.5%), vomiting (18.4%), arthralgia (13.8%), pruritus (11.5%), rash (11.1%), pyrexia (10.5%) and hypothyroidism (10.1%). JEMPERLI was permanently discontinued due to adverse reactions in 17 (3.3%) patients; most of them were immune-related events. Adverse reactions were serious in 8.7% of patients; most serious adverse reactions were immune-related adverse reactions. Refer to the JEMPERLI Prescribing Information for a full list of adverse events and the complete important safety information. About AnaptysBio AnaptysBio is a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. The Company’s proprietary anti-inflammatory pipeline includes imsidolimab, its anti-IL-36R antibody, previously referred to as ANB019, for the treatment of dermatological inflammatory diseases, including generalized pustular psoriasis, or GPP, EGFRi skin toxicity, ichthyosis, hidradenitis suppurativa and acne; its anti-PD-1 agonist program, ANB030, for treatment of certain autoimmune diseases where immune checkpoint receptors are insufficiently activated; and its BTLA modulator program, ANB032, which is broadly applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. AnaptysBio’s antibody pipeline has been developed using its proprietary somatic hypermutation, or SHM platform, which uses in vitro SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly) GSK4057190), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386), and an inflammation collaboration with Bristol-Myers Squibb, including an anti-PD-1 checkpoint agonist antibody (CC-90006) currently in clinical development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the milestones and royalty payments to be received under the GSK partnership and the timing of the release of data from our clinical trials. Statements including words such as “plan,” “continue,” “expect,” or “ongoing” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company’s ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company’s ability to fund development activities and achieve development goals, the company’s ability to protect intellectual property and other risks and uncertainties described under the heading “Risk Factors” in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Contact:Dennis MulroyAnaptysBio, Inc.858-732-0201dmulroy@anaptysbio.com
Sheridan Wyoming, April 23, 2021 (GLOBE NEWSWIRE) -- Appliqate Inc. (OTC: APQT) announces the return to in-person events with the company’s event portfolio. ELEV8, a hybrid event platform for connecting executives, and investors of blockchain, distributed ledger technologies, and digital assets, will host a two-day summit on June 2nd and 3rd in Miami during Bitcoin Week 2021. Executives from Appliqate and ELEV8 will be attending Bitcoin2021 which is one of the largest industry gatherings for bitcoin and digital assets including high profile speakers such as Jack Dorsey, co-founder, CEO & chairman of Square, Michael Saylor, Chairman & CEO of MicroStrategy, Chamath Palihapitiya, Managing Partner of Social Capital, and Senator Cynthia Lumis, State of Wyoming. The ELEV8 Summit will address NFT’s, ALT Coins, blockchain adoption, cryptocurrencies, and the state of the institutional and retail market. Participants will attend a welcome reception on the evening of June 2nd followed by a full day of content and networking on June 3rd. In 2021 bitcoin and cryptocurrency reached all-time highs resulting in unprecedented investments from corporations, institutional investors, and new retail investors. The program will feature leading organizations that are bullish within the sector and see a future where bitcoin’s market cap continues to grow into the trillions. ELEV8 will be announcing the full speaker roster in the near future. For more information visit https://www.elev8con.com/elev8-miami-summit-2021/ Past participating organizations have included NASDAQ, TDAmeritrade, State Street, JP Morgan, BlockFi, Celsius Network, Chainalysis, Galaxy Digital, Gemini, Wisdom Tree, and many other global institutions. “Appliqate is thrilled to welcome back in-person events through our portfolio company ELEV8. This last year taught us that purely virtual events struggle to fulfill our needs. We need to connect our communities with face-to-face connections so that we can recover……..this is vital .” stated Una Taylor, Founder and CEO. About ELEV8 ELEV8’s vision is that emerging new technologies such as digital assets, cryptocurrencies, AI, and blockchain create a more interconnected economic global ecosystem, working to eliminate barriers to growth and creating increased value for stakeholders across all industries. We believe future technologies will serve as the foundation for new economic systems which are more efficient, open, and accessible. Our mission is to enable that progress with industry research, distribution of the most current news, and hosting industry events that convene executives at the forefront of shaping the future of emerging technology. Our platform is home to the world’s leading tech experts; we collaborate with industry stakeholders across vertical markets and openly share insight. ELEV8 is at the forefront of shaping the future. View ELEV8’s research & industry content here: https://www.elev8con.com/industry-content/ About Appliqate Inc: Appliqate Inc is a publicly traded technology development firm that provides businesses, executives and investors access to capital and innovative solutions by utilizing platforms and business models to disrupt industry sectors. With an emphasis on media, blockchain, live entertainment, and intellectual property, the company accelerates the growth of tech solutions in these markets. Appliqate’s management team represents a unique combination of technology development, operating, investing, financial and transactional expertise. Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties, and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with the SEC including the Current Reports on Form 8-K and the Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. For more information contact: Contact: Una Taylor: Una@Appliqate.com Inquires: Investorrelations@appliqate.com www.appliqate.com
(Bloomberg) -- Puerto Rico is expected to post a cumulative budget surplus of $15.2 billion through 2035 as $123.5 billion of federal disaster funds and coronavirus relief money helps boost the local economy, according to the commonwealth’s latest fiscal plan.That surplus is crucial because the island’s financial oversight board anticipates using the money to cover Puerto Rico’s debt-service costs. The commonwealth would begin to repay principal and interest on its bonds as soon as January 2022 if it’s able to restructure its debt this year as part of its bankruptcy, according to the plan posted on its website.While the estimate pushes out anticipated deficits by four years to fiscal 2036, Puerto Rico Governor Pedro Pierluisi and the island’s legislature will need to implement structural reforms to realize the surpluses and continue economic growth after the federal cash runs out, Natalie Jaresko, the board’s executive director, told reporters Thursday.“The flow of federal reconstruction funds provides Puerto Rico with significant strength to help its economy recover, but also with an opportunity to pair this federal investment with the reforms they need to do to turn the recovery into lasting economic growth,” Jaresko said.The multi-year proposal serves as a framework for Puerto Rico’s yearly operating budgets. The board is set to vote Friday on the fiscal plan.The release comes as the board has reached tentative deals with bond insurers and rival bondholder groups that would slash $18.8 billion of debt tied to the central government by 61% to $7.4 billion. Those agreements may allow the commonwealth to resolve its bankruptcy this year.Puerto Rico’s bankruptcy started in May 2017, when it sought to restructure most of the $74 billion of debt the commonwealth and its agencies owed at that time. Puerto Rico will pay an estimated $1.6 billion in professional fees and expenses from fiscal 2018 through fiscal 2026 to restructure its obligations, according to the fiscal plan.The projected $15.2 billion surplus is for fiscal 2022 through fiscal 2035, the last year before deficits are set to return. That’s a boost from May 2020, when the board approved a fiscal plan reflecting the pandemic’s harm to the island’s economy and included a $5.8 billion surplus from fiscal 2022 through fiscal 2031, with deficits beginning in fiscal 2032.Still, the $15.2 billion cushion is smaller than the board’s pre-pandemic estimate of an $18.4 billion surplus from fiscal 2022 through fiscal 2037.If island lawmakers fail to implement structural reforms such as increasing workforce participation and making it easier to do business, the commonwealth would have a budget deficit as soon as fiscal 2023, according to the fiscal plan.The island’s economy is expected to increase this year by 1%, up from an earlier estimate of .5%. It’s projected to then grow in the next four years by a combined 1.4%, compared with an earlier forecast of a 3% contraction during that time.“Government stimulus, the stimulus that’s provided a lot of this lift, is an important element of any recovery from a severe economic crisis, but it’s not enough,” Jaresko said. “It doesn’t replace a true economic development plan.”For long-term growth, the fiscal plan includes labor and welfare reforms to boost workforce participation, improvements to K-12 education, reducing hurdles for starting and sustaining a business, and making electricity on the island more reliant and affordable.If enacted, those changes could increase revenue by nearly $31 billion from fiscal 2022 through fiscal 2051, according to the plan.(Updates with bankruptcy costs in the seventh paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
GrandVision's Annual General Meeting (AGM) 2021 adopts all resolutionsSchiphol, the Netherlands - 23 April 2021. GrandVision N.V. (Euronext: GVNV) announced today that its Annual General Meeting (AGM) has approved all resolutions on the agenda of the AGM. The adopted resolutions are listed below:• Adoption of the Annual Accounts for the financial year 2020 as drawn up by the Management Board and signed by the Managing Directors and the Supervisory Directors on 25 February 2021• Advisory vote on the approval of the remuneration report 2020• Proposal on dividend distribution for the financial year 2019 of EUR 0.35 per share• Discharge of Managing Directors for their management during the financial year 2020• Discharge of Supervisory Directors for their supervision of management during the financial year 2020• Re-appointment of Mr. P. Bolliger as Supervisory Board Director• Re-appointment of Mr. J. Cole as Supervisory Board Director• Appointment of PricewaterhouseCoopers Accountants N.V. as external auditor for financial year 2022• Authorization of Supervisory Board to issue shares or grant rights to acquire shares• Authorization of Supervisory Board to restrict or exclude pre-emptive rights• Authorization of Management Board to repurchase shares. Attachment GrandVision AGM 2021 Press Release
The women’s activist downs cheesy dough balls from The Little One, gets dressed up at SK Vintage and would take over Africa House
UK DISCLOSURE, April 23, 2021 (GLOBE NEWSWIRE) -- PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Identity of the person whose positions/dealings are being disclosed:Glazer Capital LLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficientNA(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeSignature Aviation plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:NA(e) Date position held/dealing undertaken:April 22, 2021(f) Has the discloser previously disclosed, or are they today disclosing, under the Code in respect of any other party to this offer?NO 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: 37p ordinary InterestsShort positionsNumber%Number%(1) Relevant securities owned and/or controlled: (2) Derivatives (other than options): 19,954,086 2.41% (3) Options and agreements to purchase/sell: TOTAL: 19,954,086 2.41% All interests and all short positions should be disclosed. Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other executive options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (a) Purchases and sales Class of relevant securityPurchase/sale Number of securitiesPrice per unit (b) Derivatives transactions (other than options) Class of relevant securityProduct description e.g. CFDNature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit37p ordinaryCFDIncreasing Long Position29,4085.58 USD37p ordinaryCFDIncreasing Long Position800,0005.58 USD (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitType e.g. American, European etc.Expiry dateOption money paid/ received per unit (ii) Exercising Class of relevant securityProduct description e.g. call optionNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant securityNature of dealing e.g. subscription, conversionDetailsPrice per unit (if applicable) The currency of all prices and other monetary amounts should be stated. Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: If there are no such agreements, arrangements or understandings, state “none” None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” None (c) Attachments Is a Supplemental Form 8 (Open Positions) attached?NO Date of disclosure:April 23, 2021Contact name:Megan SinclairTelephone number:212-808-7302 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
Applicant Tracking Systems Market In US 2021-2025. The analyst has been monitoring the applicant tracking systems market in the US and it is poised to grow by $ 138. 06 mn during 2021-2025, progressing at a CAGR of almost 7% during the forecast period.New York, April 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Applicant Tracking Systems Market in US 2021-2025" - https://www.reportlinker.com/p03793938/?utm_source=GNW Our report on applicant tracking systems market in the US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.The report offers an up-to-date analysis regarding the current us market scenario, latest trends and drivers, and the overall market environment. The market is driven by cost-effective and less time-consuming services and increasing enrollment of foreign students. In addition, cost-effective and less time-consuming service is anticipated to boost the growth of the market as well.The applicant tracking systems market in US analysis includes end-user segment and deployment segment.The applicant tracking systems market in the US is segmented as below:By End-User• Technology• Healthcare• Financial services• Retail• OthersBy Deployment• Cloud-based• On-premisesThis study identifies the growing emphasis on streamlining HR functions as one of the prime reasons driving the applicant tracking systems market in US growth during the next few years.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on applicant tracking systems market in the US covers the following areas:• Applicant tracking systems market in US sizing• Applicant tracking systems market in US forecast• Applicant tracking systems market in US industry analysisThis robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading applicant tracking systems market in US vendors that include Bullhorn Inc., ClearCompany Inc., Cornerstone OnDemand Inc., Greenhouse Software Inc., iCIMS Inc., International Business Machines Corp., JobDiva Inc., Oracle Corp., SwipeClock LLC, and Symphony Talent LLC. Also, the applicant tracking systems market in the US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.Read the full report: https://www.reportlinker.com/p03793938/?utm_source=GNWAbout ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________ CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001
‘I have never watched that show in my entire life, just not my cup of tea,’ says former state resident
Yahoo Finance